Collegium Pharmaceutical, Inc. Stock price

Equities

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
40.91 USD +2.45% Intraday chart for Collegium Pharmaceutical, Inc. +5.47% +32.91%
Sales 2024 * 584M Sales 2025 * 596M Capitalization 1.31B
Net income 2024 * 116M Net income 2025 * 144M EV / Sales 2024 * 2.53 x
Net Debt 2024 * 167M Net cash position 2025 * 42.16M EV / Sales 2025 * 2.12 x
P/E ratio 2024 *
13.9 x
P/E ratio 2025 *
11.1 x
Employees 197
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.96%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Collegium Pharmaceutical, Inc.

1 day+2.45%
1 week+5.47%
Current month+11.44%
1 month+11.20%
3 months+32.91%
6 months+83.04%
Current year+32.91%
More quotes
1 week
39.13
Extreme 39.13
40.91
1 month
35.91
Extreme 35.91
40.91
Current year
30.72
Extreme 30.72
40.91
1 year
20.83
Extreme 20.83
40.91
3 years
14.04
Extreme 14.04
40.91
5 years
10.01
Extreme 10.01
40.91
10 years
7.37
Extreme 7.37
40.91
More quotes
Managers TitleAgeSince
Founder 59 01-12-31
Chief Executive Officer 53 17-05-30
Director of Finance/CFO 48 21-05-23
Members of the board TitleAgeSince
Director/Board Member 76 14-12-31
Director/Board Member 66 12-07-23
Director/Board Member 70 14-01-31
More insiders
Date Price Change Volume
24-03-27 40.91 +2.45% 362,415
24-03-26 39.93 -0.57% 335,558
24-03-25 40.16 +1.11% 273,351
24-03-22 39.72 +0.15% 319,417
24-03-21 39.66 +2.24% 669,779

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
40.91 USD
Average target price
40 USD
Spread / Average Target
-2.22%
Consensus
  1. Stock
  2. Equities
  3. Stock Collegium Pharmaceutical, Inc. - Nasdaq